British scientists identified a version of a gene that may be associated with double the risk of lung failure from Covid-19, a finding that provides new insights into why some people are more susceptible than others to severe illness and which opens possibilities for targeted medicine.
A follow-up study of 33 people who received Moderna Inc.’s Covid-19 vaccine in early trials show the antibodies it induced are still present six months after the second dose.
PITTSBURGH–(BUSINESS WIRE)–ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, today announced the publication of new data by […]
